August 2006
Worldwide Biotech;Aug2006, Vol. 18 Issue 8, p2
Trade Publication
Reports on a positive study result presented by Orexo for Sublinox at Associated Professional Sleep Societies in Salt Lake City, Utah. Efficacy of Sublinox in fast sleep induction; Reason for the competitive advantage of Sublinox in comparison with existing drugs.


Related Articles

  • NEWS.  // Pharmaceutical Technology Europe;Aug2003, Vol. 15 Issue 8, p6 

    Presents news updates on the pharmaceutical industry in the U.S. as of August 2003. Decision of Diabact Ab to change its name into Orexo AB; Custom synthesis facility opened by Fisher Scientific Chemicals in Loughborough, England; Novel treatment for solid cancers to be developed by OctoPlus...

  • R&D Update.  // PharmaWatch: CNS;Feb2012, Vol. 11 Issue 2, p18 

    The article offers news briefs related to research and development in the pharmaceutical industry. Pfizer Inc. has reported positive results from Phase IV Embeda studies. Durect Corp. has announced results from the Phase III study for POSIDUR known as Bupivacaine Effectiveness and Safety (BESST)...

  • The Drug Scene -- An Update. Gerson, Charlotte // Gerson Healing Newsletter;Jul/Aug2003, Vol. 18 Issue 4, p6 

    Reports developments related to pharmaceutical industry in the U.S. as of August 2003. Issuance of patent for Zocor, a cholesterol-lowering drug and manufactured by Merck & Co. Inc.; Survey on the cause of death due to adverse drug reactions; Sales performance of the industry.

  • UK's yellow card scheme to be extended. Yamey, Gavin // BMJ: British Medical Journal (International Edition);11/20/99, Vol. 319 Issue 7221, p1322 

    Reports on the extension of Great Britain's yellow card scheme to community pharmacists, used since 1964 in the reporting of suspected drug reactions. When the extension was piloted; Number of yellow cards receives by the Medicines Control Agency each year; Purposes of the cards.

  • Build, Predict, Decide. Roberts, Sam; Samant, Asawari // Drug Discovery & Development;Sep2009, Vol. 12 Issue 8, p26 

    The article discusses the role played by pharmacokinetic/pharmacodynamic (PK/PD) modeling for drug research and safety processes and its use in the pharmaceutical industry in the U.S. It states that the changes in mechanistic and physiologically-based PK models brought challenges to building,...

  • Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of One US-Marketed and Two European-Marketed Epoetin Alfas. Lissy, Michael; Ode, Marité; Roth, Karsten // Drugs in R&D;2011, Vol. 11 Issue 1, p61 

    Background: HX575, licensed under the brand names Binocrit®, Epoetin Alfa Hexal®, and Abseamed®, was approved in 2007 as the first biosimilar recombinant human erythropoietin alfa (epoetin alfa) in the EU using Erypo®/Eprex® as reference product. Objectives: The aim of this study...

  • News in brief….  // Reactions Weekly;1/14/2006, Issue 1084, p5 

    The article offers news briefs on the pharmaceutical industry as of January 2006. According to U.S.-based researchers, concomitant fluvoxamine increases plasma caffeine concentrations in healthy subjects. The results of an interim analysis of a multicentre study on the association of hormone...

  • SECTION 3: OB/GYN.  // MPR - Urologists' Edition;Spring/Summer2011, Vol. 8 Issue 1, p30 

    The article offers information on several pharmaceutical products being used to treat vaginal infections in the practice of obstetrics. It highlights details on the applications on several drugs including indications, precautions, and adverse reactions. Drugs being presented include Betadine...

  • Do You Compute? Hovde, Mark; Weiner, Dan; Marier, Jean-Francois // Drug Discovery & Development;Sep2007, Vol. 10 Issue 9, p34 

    The article provides information about the workflows of pharmacokinetics (PK) and pharmacodynamics (PD) studies. It presents an illustration depicting the PK/PD workflows and outlines its work aspects. PK/PD workflows involve protocol design, data retrieval, regulatory-required data analysis,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics